About Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with eravacycline through investigating Gram-negative infections treated with eravacycline (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of eravacycline with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of eravacycline with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of eravacycline with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; and TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize eravacycline for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TTPH
CUSIPN/A
Phone617-715-3600
Debt
Debt-to-Equity RatioN/A
Current Ratio7.96%
Quick Ratio7.96%
Price-To-Earnings
Trailing P/E Ratio-1.21
Forward P/E Ratio-2.01
P/E GrowthN/A
Sales & Book Value
Annual Sales$9.67 million
Price / Sales16.97
Cash FlowN/A
Price / CashN/A
Book Value$2.53 per share
Price / Book1.26
Profitability
EPS (Most Recent Fiscal Year)($2.63)
Net Income$-114,750,000.00
Net Margins-1,187.17%
Return on Equity-90.75%
Return on Assets-78.57%
Miscellaneous
Employees78
Outstanding Shares51,600,000
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Frequently Asked Questions
What is Tetraphase Pharmaceuticals' stock symbol?
Tetraphase Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTPH."
How were Tetraphase Pharmaceuticals' earnings last quarter?
Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) posted its quarterly earnings results on Thursday, March, 8th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.64) by $0.18. The biopharmaceutical company had revenue of $2.53 million for the quarter, compared to analyst estimates of $2.26 million. Tetraphase Pharmaceuticals had a negative net margin of 1,187.17% and a negative return on equity of 90.75%. View Tetraphase Pharmaceuticals' Earnings History.
When is Tetraphase Pharmaceuticals' next earnings date?
What price target have analysts set for TTPH?
9 brokers have issued 1-year price objectives for Tetraphase Pharmaceuticals' stock. Their forecasts range from $3.00 to $11.00. On average, they anticipate Tetraphase Pharmaceuticals' share price to reach $7.1429 in the next twelve months. View Analyst Ratings for Tetraphase Pharmaceuticals.
What are Wall Street analysts saying about Tetraphase Pharmaceuticals stock?
Here are some recent quotes from research analysts about Tetraphase Pharmaceuticals stock:
- 1. Needham & Company LLC analysts commented, "Tetraphase reported 4Q17 financial results yesterday after market close and we spoke w/ mgmt for an update. As a reminder, the company announced last month that the IV eravacycline Phase 3 IGNITE3 trial in complicated Urinary Tract Infections (cUTI) missed the primary endpoint. We do not expect the company to continue development in cUTI, nor to pursue development of an oral formulation of the drug. IV eravacycline is under review for complicated Intra- Abdominal Infections (cIAI) in both the U.S. and E.U. We expect approval by the 8/28/18 PDUFA date in the U.S. and in 2H18 in Europe. Maintain HOLD rating, based on concerns around commercial potential for lead asset IV eravacycline." (3/7/2018)
- 2. HC Wainwright analysts commented, "a Highly Favorable Risk/Reward; Affirm Buy Stock Data 02/05/2018 Price $5.19 Exchange NASDAQ Price Target $17.00 52-Week High $9.93 52-Week Low $4.04 Enterprise Value (M) $106.6 Market Cap (M) $268 Public Market Float (M) 37.5 Shares Outstanding (M) 51.6 3 Month Avg Volume 477,304 Short Interest (M) 2.97 Shares Outstanding (M): Figure shown is as of January 24, 2018. Balance Sheet Metrics Cash (M) $161.4 Total Debt (M) $0.0 Total Cash/Share $3.13 Book Value/Share $2.78 Cash (M): Figure shown is as of September 30, 2017. EPS Diluted Full Year – Dec 2016A 2017E 2018E 1Q (0.46) (0.79)A (0.56) 2Q (0.47) (0.83)A (0.55) 3Q (0.58) (0.63)A (0.54) 4Q (0.61) (0.60) (0.52) FY (2.11) (2.80) (2.17) Revenue ($M) Full Year – Dec 2016A 2017E 2018E 1Q 2.0 1.5A 1.5 2Q 1.2 1.6A 1.0 3Q 0.9 4.1A 1.2 4Q 1.1 2.0 1.5 FY 5.1 9.1 5.2 10 8 6 4 2 FEB- 17 J UN- 17 OCT- 17 FEB- 18 20 15 10 5 0 Vol. (mil) Price cUTI: We believe IGNITE3 will be a solid, clean win." (2/6/2018)
- 3. According to Zacks Investment Research, "Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company's product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. " (1/12/2018)
Who are some of Tetraphase Pharmaceuticals' key competitors?
Some companies that are related to Tetraphase Pharmaceuticals include Geron (GERN), Endocyte (ECYT), Rhythm Pharmaceuticals (RYTM), Ziopharm Oncology (ZIOP), Clementia Pharmaceuticals (CMTA), AC Immune (ACIU), Lannett (LCI), Arrowhead Pharmaceuticals (ARWR), Achaogen (AKAO), Dicerna Pharmaceuticals (DRNA), Five Prime Therapeutics (FPRX), Odonate Therapeutics (ODT), TiGenix - American Depositary Shares (TIG), Theratechnologies (THERF) and Aclaris Therapeutics (ACRS).
Who are Tetraphase Pharmaceuticals' key executives?
Tetraphase Pharmaceuticals' management team includes the folowing people:
- Mr. Guy MacDonald B.Sc., B.Sc, CEO, Pres & Director (Age 59)
- Dr. Jacques Dumas Ph.D., Chief Scientific Officer (Age 52)
- Ms. Maria D. Stahl, Sr. VP & Gen. Counsel (Age 47)
- Mr. Larry G. Edwards, Chief Operating Officer
- Mr. Paul J. Fanning, Sr. VP of HR (Age 60)
Has Tetraphase Pharmaceuticals been receiving favorable news coverage?
Press coverage about TTPH stock has been trending somewhat positive recently, Accern reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Tetraphase Pharmaceuticals earned a media sentiment score of 0.21 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 45.41 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of Tetraphase Pharmaceuticals?
Shares of TTPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tetraphase Pharmaceuticals' stock price today?
One share of TTPH stock can currently be purchased for approximately $3.18.
How big of a company is Tetraphase Pharmaceuticals?
Tetraphase Pharmaceuticals has a market capitalization of $163.56 million and generates $9.67 million in revenue each year. The biopharmaceutical company earns $-114,750,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. Tetraphase Pharmaceuticals employs 78 workers across the globe.
How can I contact Tetraphase Pharmaceuticals?
Tetraphase Pharmaceuticals' mailing address is 480 ARSENAL STREET SUITE 110, WATERTOWN MA, 02472. The biopharmaceutical company can be reached via phone at 617-715-3600 or via email at [email protected]
MarketBeat Community Rating for Tetraphase Pharmaceuticals (TTPH)
MarketBeat's community ratings are surveys of what our community members think about Tetraphase Pharmaceuticals and other stocks. Vote "Outperform" if you believe TTPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
9 Wall Street analysts have issued ratings and price targets for Tetraphase Pharmaceuticals in the last 12 months. Their average twelve-month price target is $7.1429, suggesting that the stock has a possible upside of 124.62%. The high price target for TTPH is $11.00 and the low price target for TTPH is $3.00. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.63 | 2.80 | 2.67 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $7.1429 | $7.1429 | $17.00 | $14.00 |
| Price Target Upside: | 124.62% upside | 157.86% upside | 191.10% upside | 93.10% upside |
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Consensus Price Target History
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Tetraphase Pharmaceuticals (NASDAQ TTPH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 58.51%
Tetraphase Pharmaceuticals (NASDAQ TTPH) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/30/2018 | Jacques Dumas | Insider | Sell | 8,750 | $6.22 | $54,425.00 | 8,750 |  |
| 1/9/2018 | Jacques Dumas | Insider | Sell | 7,167 | $6.21 | $44,507.07 | | |
| 11/29/2017 | L Patrick Gage | Director | Buy | 3,880 | $6.45 | $25,026.00 | 38,880 | |
| 10/31/2017 | Jacques Dumas | Insider | Sell | 8,750 | $6.03 | $52,762.50 | 8,750 | |
| 8/22/2017 | Jacques Dumas | Insider | Sell | 17,500 | $6.00 | $105,000.00 | 17,500 | |
| 8/17/2017 | Jacques Dumas | Insider | Sell | 7,155 | $5.86 | $41,928.30 | | |
| 3/15/2017 | L Patrick Gage | Director | Buy | 11,000 | $7.49 | $82,390.00 | 35,000 | |
| 9/1/2015 | Guy Macdonald | insider | Sell | 10,000 | $41.57 | $415,700.00 | 52,000 | |
| 8/14/2015 | David Charles Lubner | CFO | Sell | 9,500 | $42.92 | $407,740.00 | | |
| 8/13/2015 | Patrick Taylor Horn | Insider | Sell | 10,000 | $44.69 | $446,900.00 | | |
| 8/12/2015 | L Patrick Gage | Director | Sell | 15,000 | $45.00 | $675,000.00 | | |
| 7/20/2015 | Guy Macdonald | Insider | Sell | 15,000 | $50.72 | $760,800.00 | | |
| 7/14/2015 | David Charles Lubner | CFO | Sell | 7,500 | $48.92 | $366,900.00 | | |
| 7/13/2015 | Patrick Taylor Horn | Insider | Sell | 10,000 | $48.93 | $489,300.00 | | |
| 7/6/2015 | John Craig Thompson | COO | Sell | 10,000 | $47.91 | $479,100.00 | | |
| 7/1/2015 | Guy Macdonald | Insider | Sell | 10,000 | $47.92 | $479,200.00 | | |
| 6/15/2015 | David Charles Lubner | CFO | Sell | 17,500 | $41.45 | $725,375.00 | | |
| 6/15/2015 | John Craig Thompson | COO | Sell | 10,000 | $41.51 | $415,100.00 | | |
| 6/8/2015 | John Craig Thompson | COO | Sell | 22,499 | $43.26 | $973,306.74 | | |
| 6/1/2015 | Guy Macdonald | Insider | Sell | 16,087 | $41.89 | $673,884.43 | | |
| 5/11/2015 | Guy Macdonald | Insider | Sell | 20,000 | $41.51 | $830,200.00 | | |
| 1/20/2015 | Guy Macdonald | Insider | Sell | 34,135 | $36.59 | $1,248,999.65 | | |
| 10/2/2014 | John Gordon Freund | Director | Sell | 247,734 | $20.88 | $5,172,685.92 | | |
| 10/1/2014 | John Gordon Freund | Director | Sell | 142,146 | $20.84 | $2,962,322.64 | | |
| 9/30/2014 | John Gordon Freund | Director | Sell | 152,266 | $20.18 | $3,072,727.88 | | |
| 9/29/2014 | John Gordon Freund | Director | Sell | 95,648 | $20.19 | $1,931,133.12 | | |
| 9/23/2014 | Guy Macdonald | Insider | Sell | 10,000 | $18.47 | $184,700.00 | | |
| 9/17/2014 | Guy Macdonald | Insider | Sell | 10,000 | $18.00 | $180,000.00 | | |
| 9/17/2014 | John Gordon Freund | Director | Sell | 144,356 | $17.21 | $2,484,366.76 | | |
| 9/12/2014 | John Gordon Freund | Director | Sell | 55,644 | $17.01 | $946,504.44 | | |
| 9/8/2014 | John Gordon Freund | Director | Sell | 16,700 | $15.01 | $250,667.00 | | |
| 9/4/2014 | John Gordon Freund | Director | Sell | 183,300 | $15.05 | $2,758,665.00 | | |
| 9/3/2014 | John Gordon Freund | Director | Sell | 142,100 | $15.04 | $2,137,184.00 | | |
| 8/20/2014 | Guy Macdonald | Insider | Sell | 10,000 | $11.59 | $115,900.00 | | |
| 7/18/2014 | Guy Macdonald | Insider | Sell | 15,000 | $10.61 | $159,150.00 | | |
| 6/23/2014 | John Gordon Freund | Director | Sell | 47,184 | $13.77 | $649,723.68 | | |
| 6/20/2014 | John Gordon Freund | Director | Sell | 152,816 | $13.39 | $2,046,206.24 | | |
| 6/17/2014 | David Charles Lubner | CFO | Sell | 13,530 | $12.51 | $169,260.30 | | |
| 6/17/2014 | Guy Macdonald | Insider | Sell | 15,000 | $12.28 | $184,200.00 | | |
| 5/19/2014 | Guy Macdonald | Insider | Sell | 15,000 | $9.00 | $135,000.00 | | |
| 5/19/2014 | Steven Ph.D. Gullans | Director | Buy | 25,000 | $9.24 | $231,000.00 | 25,000 | |
| 5/14/2014 | L Patrick Gage | Director | Buy | 5,000 | $9.25 | $46,250.00 | 5,000 | |
| 4/14/2014 | Guy Macdonald | Insider | Sell | 15,000 | $9.69 | $145,350.00 | | |
| 3/20/2014 | Joyce Sutcliffe | SVP | Sell | 11,494 | $12.41 | $142,640.54 | 17,242 | |
| 3/6/2014 | David Charles Lubner | CFO | Sell | 4,510 | $13.65 | $61,561.50 | 91,993 | |
| 2/20/2014 | Joyce Sutcliffe | SVP | Sell | 11,494 | $14.00 | $160,916.00 | 28,736 | |
| 2/12/2014 | David Charles Lubner | CFO | Sell | 4,506 | $13.92 | $62,723.52 | 96,503 | |
| 2/7/2014 | David Charles Lubner | CFO | Sell | 9,928 | $14.22 | $141,176.16 | 101,009 | |
| 2/5/2014 | Joyce Sutcliffe | SVP | Sell | 11,494 | $13.93 | $160,111.42 | 40,230 | |
| 9/18/2013 | Ventures Vi Lp Cmea | major shareholder | Sell | 100,000 | $10.20 | $1,020,000.00 | | |
| 9/17/2013 | Ventures Vi Lp Cmea | major shareholder | Sell | 53,468 | $9.26 | $495,113.68 | | |
| 3/25/2013 | John Gordon Freund | Director | Buy | 681,012 | $7.00 | $4,767,084.00 | | |
| 3/25/2013 | Medical Fund Lp Excel | Major Shareholder | Buy | 496,121 | $7.00 | $3,472,847.00 | | |
| 3/20/2013 | Fmr Llc | Insider | Buy | 642,857 | $7.00 | $4,499,999.00 | | |
(Data available from 1/1/2013 forward)
Tetraphase Pharmaceuticals (NASDAQ TTPH) News Headlines
| Source: |
|
Tetraphase Pharmaceuticals (NASDAQ:TTPH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Income Statement, Balance Sheet and Cash Flow Statement
Tetraphase Pharmaceuticals (NASDAQ TTPH) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
